This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Houlihan, H. H.
Right arrow Articles by Rybak, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Houlihan, H. H.
Right arrow Articles by Rybak, M. J.

 Previous Article  |  Next Article 

Antimicrob. Agents Chemother., 11 1997, 2497-2501, Vol 41, No. 11
Copyright © 1997 by the American Society for Microbiology. All rights reserved.

Pharmacodynamics of vancomycin alone and in combination with gentamicin at various dosing intervals against methicillin-resistant Staphylococcus aureus-infected fibrin-platelet clots in an in vitro infection model

HH Houlihan, RC Mercier and MJ Rybak
Department of Pharmacy Services, Detroit Receiving Hospital/University Health Center and College of Pharmacy and Allied Health Professions, Michigan 48201, USA.

We compared the pharmacodynamic activities of vancomycin with or without gentamicin in an in vitro infection model with methicilin- resistant Staphylococcus aureus-infected fibrin-platelet clots. Infected fibrin-platelet clots (FPCs) were prepared with human cryoprecipitate, human platelets, thrombin, and the organism (approximately 10[9] CFU of MRSA-494/g) and were suspended with monofilament line in an infection model capable of simulating human pharmacokinetics. Antibiotics were bolused to simulate vancomycin regimens of 2 g every 24 h (q24h), 1 g q12h, 500 mg q6h, and continuous infusion (steady-state concentration of 20 microg/ml) and gentamicin regimens of 1.5 mg/kg of body weight q12h and 5 mg/kg once daily (q.d.). Model experiments were performed in duplicate over 72 h. FPCs were removed from the models in quadruplicate at 0, 8, 24, 32, 48, 72 h, weighed, homogenized, diluted, and plated to determine colony counts. The inoculum density at 72 h was used to compare bactericidal activities between the regimens. All regimens containing vancomycin significantly decreased the bacterial inoculum compared to the growth control (P < 0.001). Vancomycin monotherapy regimens were similar in bacterial kill regardless of dosing frequency. The addition of gentamicin (either q12h or q.d.) significantly improved the bactericidal activity of the vancomycin q6h, q12h, and q24h regimens (P < 0.001). The greatest reduction in bacterial density at 72 h (P < 0.001) and the most rapid rate of kill (time to 99.9% killing) were achieved with the regimen consisting of 2 g of vancomycin q24h plus gentamicin (q.d. or q12h).


This article has been cited by other articles:

  • Nguyen, H. M., Graber, C. J. (2009). Limitations of antibiotic options for invasive infections caused by methicillin-resistant Staphylococcus aureus: is combination therapy the answer?. J Antimicrob Chemother 0: dkp377v1-dkp377 [Abstract] [Full Text]  
  • Andes, D., Craig, W. A. (2007). In Vivo Pharmacodynamic Activity of the Glycopeptide Dalbavancin. Antimicrob. Agents Chemother. 51: 1633-1642 [Abstract] [Full Text]  
  • Lee, D.-G., Chun, H.-S., Yim, D.-S., Choi, S.-M., Choi, J.-H., Yoo, J.-H., Shin, W.-S., Kang, M.-W. (2003). Efficacies of Vancomycin, Arbekacin, and Gentamicin Alone or in Combination against Methicillin-Resistant Staphylococcus aureus in an In Vitro Infective Endocarditis Model. Antimicrob. Agents Chemother. 47: 3768-3773 [Abstract] [Full Text]  
  • Boylan, C. J., Campanale, K., Iversen, P. W., Phillips, D. L., Zeckel, M. L., Parr, T. R. Jr. (2003). Pharmacodynamics of Oritavancin (LY333328) in a Neutropenic-Mouse Thigh Model of Staphylococcus aureus Infection. Antimicrob. Agents Chemother. 47: 1700-1706 [Abstract] [Full Text]  
  • Cohen, E., Dadashev, A., Drucker, M., Samra, Z., Rubinstein, E., Garty, M. (2002). Once-daily versus twice-daily intravenous administration of vancomycin for infections in hospitalized patients. J Antimicrob Chemother 49: 155-160 [Abstract] [Full Text]  
  • Wysocki, M., Delatour, F., Faurisson, F., Rauss, A., Pean, Y., Misset, B., Thomas, F., Timsit, J.-F., Similowski, T., Mentec, H., Mier, L., Dreyfuss, D., The Study Group, (2001). Continuous versus Intermittent Infusion of Vancomycin in Severe Staphylococcal Infections: Prospective Multicenter Randomized Study. Antimicrob. Agents Chemother. 45: 2460-2467 [Abstract] [Full Text]  
  • Aeschlimann, J. R., Allen, G. P., Hershberger, E., Rybak, M. J. (2000). Activities of LY333328 and Vancomycin Administered Alone or in Combination with Gentamicin against Three Strains of Vancomycin-Intermediate Staphylococcus aureus in an In Vitro Pharmacodynamic Infection Model. Antimicrob. Agents Chemother. 44: 2991-2998 [Abstract] [Full Text]  
  • Rochon-Edouard, S., Pestel-Caron, M., Lemeland, J.-F., Caron, F. (2000). In Vitro Synergistic Effects of Double and Triple Combinations of beta -Lactams, Vancomycin, and Netilmicin against Methicillin-Resistant Staphylococcus aureus Strains. Antimicrob. Agents Chemother. 44: 3055-3060 [Abstract] [Full Text]  
  • Mercier, R.-C., Rybak, M. J., Bayer, A. S., Yeaman, M. R. (2000). Influence of Platelets and Platelet Microbicidal Protein Susceptibility on the Fate of Staphylococcus aureus in an In Vitro Model of Infective Endocarditis. Infect. Immun. 68: 4699-4705 [Abstract] [Full Text]  
  • Aeschlimann, J. R., Hershberger, E., Rybak, M. J. (1999). Analysis of Vancomycin Population Susceptibility Profiles, Killing Activity, and Postantibiotic Effect against Vancomycin-Intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 43: 1914-1918 [Abstract] [Full Text]  
  • Amorena, B., Gracia, E., Monzon, M., Leiva, J., Oteiza, C., Perez, M., Alabart, J.-L., Hernandez-Yago, J. (1999). Antibiotic susceptibility assay for Staphylococcus aureus in biofilms developed in vitro. J Antimicrob Chemother 44: 43-55 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»